Official Title
Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial
Brief Summary

The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019 (COVID-19). Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling through these receptors. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering investigational treatments administration to patients enrolled in the CORIMUNO-19 cohort (NCT04324047). Sarilumab+Azithromycin+Hydroxychloroquine, or Sarilumab only will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation. All patients will receive standard of care along with randomized investigational treatments. Outcomes of included patients will be compared between groups as well as with outcomes of patients in the CORIMUNO-19 cohort treated with other immune modulators or standard of care.

Recruiting
COVID19
SARS-CoV-2 Infection

Drug: Sarilumab
Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
Sarilumab
Sarilumab + Azithromycin + Hydroxychloroquine

Drug: Azithromycin
Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
Sarilumab + Azithromycin + Hydroxychloroquine

Drug: Hydroxychloroquine
Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
Sarilumab + Azithromycin + Hydroxychloroquine

Eligibility Criteria

Inclusion Criteria:

- Patients included in the CORIMUNO-19 cohort (NCT04324047)

- COVID-19 cases not requiring ICU at admission with moderate or severe pneumopathy according to the WHO Criteria of severity of COVID pneumopathy: - Moderate cases: Cases meeting all of the following criteria: [Showing fever and respiratory symptoms with radiological findings of pneumonia] AND [Requiring between 3L/min and 5L/min of oxygen to maintain SpO2>97%] OR - Severe cases: Cases meeting any of the following criteria: [Respiratory distress ( ≥ 30 breaths/ min)] OR [Oxygen saturation≤93% at rest in ambient air; or Oxygen saturation ≤97 % with O2 > 5L/min] OR [PaO2/FiO2 ≤ 300mmHg]

Exclusion Criteria:

1. Patients with exclusion criteria to the CORIMUNO-19 cohort.

2. Respiratory failure requiring non invasive or mechanical ventilation

3. Patients requiring intensive care

4. Do-not-resuscitate order (DNR order)

5. Known hypersensitivity to sarilumab or to any of their excipients.

6. Known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, G6PD deficiency and QT prolongation

7. Known contra-indication to azithromycin: including hypersensitivity/allergy and QT prolongation

8. Pregnancy or breastfeeding

9. Current documented bacterial infection.

10. Patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: - Absolute neutrophil count (ANC) ≤ 1.0 x 109/L - Haemoglobin level: no limitation - Platelets (PLT) < 50 G /L - SGOT or SGPT > 5N

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years~Maximum: 80 Years
Countries
France
Contacts

David Saadoun, MD PhD
673081143 +33
david.saadoun@aphp.fr

Matthieu Resche-Rigon, MD PhD
685740240 +33
matthieu.resche-rigon@u-paris.fr

Assistance Publique - Hôpitaux de Paris
NCT Number
MeSH Terms
Hydroxychloroquine